Head-to-head evidence
ABBV-295 vs MET-233i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
ABBV-295
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07291232 (registry estimate)
MET-233i
Developed by Pfizer
NCT07022977 · Phase 1 · completed
Participants were randomly assigned to MET233 or a matching placebo, with everyone blinded to the assignment, which is a sound safety-testing design. However, the trial's main measure was side-effect occurrence rather than weight loss, which was only a secondary measure, and results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · MET-233i's landscape